{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:57:01Z","timestamp":1781636221908,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Minufiya University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a significant complication of hepatitis C virus (HCV) infection. This study investigates the potential of relative telomere length as a predictive biomarker in HCC patients, comparing non-DAA treatment groups with post-direct-acting antiviral (DAA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Telomere length was measured using quantitative real-time PCR (qPCR) in tumor and adjacent non-tumorous tissues from 41 HCC patients, divided into de novo (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916) and post-DAA (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925) groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean telomere length was significantly higher in tumor than non-tumorous tissues (3.39\u2009\u00b1\u20094.05 compared to 1.01\u2009\u00b1\u20090.04;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Mean telomere length varied significantly between groups, with non-DAA group showing higher tumor telomere length (5.15\u2009\u00b1\u20094.88) compared to post-DAA patients (2.26\u2009\u00b1\u20093.01). Receiver Operating Characteristic (ROC) curve analysis revealed fair discriminatory ability in the non-DAA group (AUC 0.706, 95% CI: 0.524\u20130.888,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). A significant correlation between tumor telomere length and carcinoembryonic antigen was observed in the post-DAA group. Non-DAA group showed more aggressive tumor grades, while post-DAA patients had better liver function. No significant association was found between relative telomere length and HCC risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant telomere length alterations and clinicopathological differences highlight molecular heterogeneity in HCV-related HCC, particularly post-DAA. While Relative telomere length (RTL) did not predict HCC risk, its correlations with tumor markers suggest potential as a prognostic biomarker, warranting further research in larger cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15339-7","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:43:00Z","timestamp":1771850580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relative telomer length as a potential biomarker in hepatocellular carcinoma: a comparative study of HCV patients treated with direct antiviral agent"],"prefix":"10.1186","volume":"26","author":[{"given":"Marwa","family":"Helal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf A.","family":"Basuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"El Gendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"15339_CR1","first-page":"209","volume":"72","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Weiderpassand E, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries %J. CA Cancer J Clin. 2022;72(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"15339_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma %J. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"3","key":"15339_CR3","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1053\/j.gastro.2019.05.001","volume":"157","author":"S Caruso","year":"2019","unstructured":"Caruso S, Calderaro J. Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma %J. Gastroenterology. 2019;157(3):760\u201376.","journal-title":"Gastroenterology"},{"issue":"1","key":"15339_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-021-00245-6","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanuevaand A, et al. Hepatocellular Carcinoma %J Nat Rev Dis Primers. 2021;7(1):7.","journal-title":"Hepatocellular Carcinoma %J Nat Rev Dis Primers"},{"issue":"38","key":"15339_CR5","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.3748\/wjg.v26.i38.5759","volume":"26","author":"S D\u2019Souza","year":"2020","unstructured":"D\u2019Souza S, Lau KC, Coffinand CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759\u201383.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"15339_CR6","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","volume":"22","author":"T Vescovo","year":"2016","unstructured":"Vescovo T, Refolo G, Vitagliano G, Fimiaand GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22(10):853\u201361.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"15339_CR7","first-page":"553","volume":"18","author":"M Ringehan","year":"2018","unstructured":"Ringehan M, McKeatingand JA, Protzer U. Chronic liver diseases, hepatocellular carcinoma and the liver microenvironment %J. Nat Rev Immunol. 2018;18(9):553\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"15339_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/2159-8290.CD-16-0062","volume":"6","author":"JW Shay","year":"2016","unstructured":"Shay JW. Role of telomeres and telomerase in aging and cancer %J. Cancer Discov. 2016;6(6):584\u201393.","journal-title":"Cancer Discov"},{"issue":"5","key":"15339_CR9","first-page":"1605","volume":"160","author":"KL Rudolph","year":"2021","unstructured":"Rudolph KL, Chang S, Milliganand S, et al. Telomeres Telomerase Liver Stem Cell Dis %J Gastroenterol. 2021;160(5):1605\u201319.","journal-title":"Telomeres Telomerase Liver Stem Cell Dis %J Gastroenterol"},{"key":"15339_CR10","doi-asserted-by":"crossref","unstructured":"Cleal K, K Norrisand D, Baird. Telomere length dynamics and the evolution of cancer genome architecture. Int J Mol Sci. 2018;19(2):482.","DOI":"10.3390\/ijms19020482"},{"key":"15339_CR11","unstructured":"Calado RT, Young NS. Telomeres in disease. J F1000 Prime Rep. 2015;7:(11):2407."},{"issue":"4","key":"15339_CR12","first-page":"245","volume":"21","author":"PA Farazi","year":"2021","unstructured":"Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from gene to environment %J. Nat Rev Cancer. 2021;21(4):245\u201361.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"15339_CR13","first-page":"921","volume":"72","author":"J-C Nault","year":"2020","unstructured":"Nault J-C, Zucman-Rossi J. Telomerase reverse transcriptase promoter mutation is a key driver of hepatocellular carcinoma progression %J. Hepatology. 2020;72(3):921\u201335.","journal-title":"Hepatology"},{"issue":"6","key":"15339_CR14","first-page":"615","volume":"285","author":"SE Bojesen","year":"2019","unstructured":"Bojesen SE. Telomeres and human health %J. J Intern Med. 2019;285(6):615\u201326.","journal-title":"J Intern Med"},{"issue":"16","key":"15339_CR15","first-page":"3247","volume":"80","author":"J Vinagre","year":"2020","unstructured":"Vinagre J, Almeida A. TERT promoter mutations in cancer: an emerging molecular driver %. J Cancer Res Ther. 2020;80(16):3247\u201353.","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"15339_CR16","first-page":"187","volume":"17","author":"NW Kim","year":"2017","unstructured":"Kim NW, Wrightand WE, Shay JW. Telomerase reactivation mechanisms in cancer %. J Nat Rev Cancer. 2017;17(3):187\u201398.","journal-title":"J Nat Rev Cancer"},{"issue":"1","key":"15339_CR17","first-page":"1411","volume":"8","author":"FP Barthel","year":"2017","unstructured":"Barthel FP, Wei W, Tangand M, et al. Syst Anal Telomere Length Somatic Alterations Cancer Types %J Nat Commun. 2017;8(1):1411.","journal-title":"Syst Anal Telomere Length Somatic Alterations Cancer Types %J Nat Commun"},{"issue":"5","key":"15339_CR18","first-page":"341","volume":"21","author":"JL Stern","year":"2020","unstructured":"Stern JL, Zyner KG, Pickettand HA, et al. Telomeric alterations in cancer progression %J. Nat Rev Genet. 2020;21(5):341\u201352.","journal-title":"Nat Rev Genet"},{"issue":"9","key":"15339_CR19","first-page":"855","volume":"26","author":"JW Shay","year":"2020","unstructured":"Shay JW, Wright WE. Telomerase therapeutics: challenge in targeting a unique cellular property %J. Trends Mol Med. 2020;26(9):855\u201366.","journal-title":"Trends Mol Med"},{"issue":"3\u20134","key":"15339_CR20","first-page":"187","volume":"23","author":"CM Counter","year":"2018","unstructured":"Counter CM. Telomerase activity in human cancer %J. Crit Rev Oncog. 2018;23(3\u20134):187\u201398.","journal-title":"Crit Rev Oncog"},{"issue":"6","key":"15339_CR21","first-page":"1322","volume":"40","author":"M Umer","year":"2020","unstructured":"Umer M, Nawaz K, Khabirand M, et al. Long-term outcomes of direct-acting antiviral therapy in hepatitis C patients: A systematic review %J. Liver Int. 2020;40(6):1322\u201333.","journal-title":"Liver Int"},{"issue":"Suppl 2","key":"15339_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt %J. Liver Int. 2011;31(Suppl 2):61\u201380.","journal-title":"Liver Int"},{"key":"15339_CR23","doi-asserted-by":"crossref","unstructured":"Giovannini C, Fornari F, Indio V, Trer\u00e8 D, Renzulli M, Vasuriand F, et al. Direct antiviral treatments for hepatitis C virus have off-target effects of oncologic relevance in hepatocellular carcinoma %. J cancers (Basel). 2020;12:2674.","DOI":"10.3390\/cancers12092674"},{"key":"15339_CR24","doi-asserted-by":"crossref","unstructured":"Lithy RM, Elbaz T, Abdelmaksoud AH, Nabil MM, Rashed N, Omranand D, et al. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. J Eur J Gastroenterol Hepatol 2020. 2022;34(2):227-34.","DOI":"10.1097\/MEG.0000000000001972"},{"key":"15339_CR25","doi-asserted-by":"publisher","first-page":"6770","DOI":"10.3748\/wjg.v26.i43.6770","volume":"26","author":"CM Muzica","year":"2020","unstructured":"Muzica CM, Stanciu C, Huiban L, Singeap A-M, Sfarti C, Zenoviaand S, et al. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: a debate near the end %J. World J Gastroenterol. 2020;26:6770\u201381.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"15339_CR26","first-page":"1210","volume":"70","author":"D Duggan","year":"2019","unstructured":"Duggan D, Mazar J, Raoand A, et al. Telomere dynamics in viral hepatitis and liver disease progression %J. Hepatology. 2019;70(4):1210\u201322.","journal-title":"Hepatology"},{"key":"15339_CR27","first-page":"151","volume":"163","author":"AS Alzahrani","year":"2019","unstructured":"Alzahrani AS. The role of telomeres and telomerase in human diseases %J. Prog Mol Biol Transl Sci. 2019;163:151\u201379.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"3","key":"15339_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3350\/cmh.2024.0155","volume":"30","author":"CF Huang","year":"2024","unstructured":"Huang CF, Awad MH, Gal-Tanamyand M, Yu ML. Unmet needs in the post-direct-acting antivirals era: the risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clin Mol Hepatol. 2024;30(3):326\u201344.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"15339_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10238-025-01608-z","volume":"25","author":"X Huang","year":"2025","unstructured":"Huang X, Huang L, Lu J, Cheng L, Wu D, Li L, et al. The relationship between telomere length and aging-related diseases. Clin Exp Med. 2025;25(1):72.","journal-title":"Clin Exp Med"},{"issue":"7","key":"15339_CR30","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.prp.2017.03.002","volume":"213","author":"L Zhou","year":"2017","unstructured":"Zhou L, Rui JA, Zhou WX, Wang SB, Chenand SG, Qu Q. Edmondson-Steiner grade: a crucial predictor of recurrence and survival in hepatocellular carcinoma without microvascular invasio. Pathol Res Pract. 2017;213(7):824\u201330.","journal-title":"Pathol Res Pract"},{"key":"15339_CR31","doi-asserted-by":"crossref","unstructured":"Molina-Carrion S, Brochado-Kith O, Gonzalez-Garcia J, Berenguer J, Diez C, Llop E, et al. Telomere length increase in HIV\/HCV-Coinfected patients with cirrhosis after HCV eradication with Direct-Acting antivirals. J Clin Med. 2020;9(8):2407.","DOI":"10.3390\/jcm9082407"},{"key":"15339_CR32","doi-asserted-by":"crossref","unstructured":"Feng W, Yu D, Li B, Luo OY, Xu T, Caoand Y, et al. Paired assess liver telomere lengths hepatocellular cancer is reliable predictor disease persistence. Biosci Rep. 2017;37(2):BSR 20160621.","DOI":"10.1042\/BSR20160621"},{"issue":"4","key":"15339_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/MEG.0000000000001306","volume":"31","author":"HM Demerdash","year":"2019","unstructured":"Demerdash HM, Elyamanyand AS, Arida E. Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis. Eur J Gastroenterol Hepatol. 2019;31(4):494\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"15339_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jhep.2020.11.052","volume":"74","author":"M Ningarhari","year":"2021","unstructured":"Ningarhari M, Caruso S, Hirsch TZ, Bayard Q, Franconi A, Vedie AL, et al. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol. 2021;74(5):1155\u201366.","journal-title":"J Hepatol"},{"key":"15339_CR35","doi-asserted-by":"crossref","unstructured":"Loukopoulou C, Nikolouzakis T, Koliarakis I, Vakonakiand E, Tsiaoussis J. Telomere length and telomerase activity as potential biomarkers for gastrointestinal cancer.\u00a0Cancers (Basel). 2024;16(19):3370.","DOI":"10.3390\/cancers16193370"},{"issue":"11","key":"15339_CR36","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1093\/annonc\/mdn405","volume":"19","author":"CM Raynaud","year":"2008","unstructured":"Raynaud CM, Jang SJ, Nuciforo P, Lantuejoul S, Brambilla E, Mounier N, et al. Telomere shortening is correlated with the DNA damage response and telomeric protein down-regulation in colorectal preneoplastic lesions. Ann Oncol. 2008;19(11):1875\u201381.","journal-title":"Ann Oncol"},{"issue":"1","key":"15339_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/jgh.15659","volume":"37","author":"E Ogawa","year":"2022","unstructured":"Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A. G Kyushu university liver disease Study, Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. J Gastroenterol Hepatol. 2022;37(1):190\u20139.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"15339_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14787210.2021.1951230","volume":"20","author":"T Elbaz","year":"2022","unstructured":"Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, et al. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Rev Anti-infect Ther. 2022;20(2):307\u201314.","journal-title":"Expert Rev Anti-infect Ther"},{"issue":"1","key":"15339_CR39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00535-020-01747-y","volume":"56","author":"H Ochi","year":"2021","unstructured":"Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, et al. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol. 2021;56(1):90\u2013100.","journal-title":"J Gastroenterol"},{"issue":"4","key":"15339_CR40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/HEP.0000000000000608","volume":"79","author":"H Gellert-Kristensen","year":"2024","unstructured":"Gellert-Kristensen H, Bojesen SE, Tybjaerg Hansenand A, Stender S. Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population. Hepatology. 2024;79(4):857\u201368.","journal-title":"Hepatology"},{"issue":"2","key":"15339_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.21873\/anticanres.11358","volume":"37","author":"H Zeng","year":"2017","unstructured":"Zeng H, Wu HC, Wang Q, Yang HI, Chen CJ, Santellaand RM, et al. Telomere length and risk of hepatocellular carcinoma: a nested case-control study in Taiwan cancer screening program cohort. Anticancer Res. 2017;37(2):637\u201344.","journal-title":"Anticancer Res"},{"issue":"8","key":"15339_CR42","doi-asserted-by":"publisher","first-page":"9937","DOI":"10.1002\/cam4.5702","volume":"12","author":"C Yang","year":"2023","unstructured":"Yang C, Wu X, Chenand S, Xiang B. Association between telomere length and hepatocellular carcinoma risk: a Mendelian randomization study. Cancer Med. 2023;12(8):9937\u201344.","journal-title":"Cancer Med"},{"issue":"4","key":"15339_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/carcin\/bgx021","volume":"38","author":"S Wan","year":"2017","unstructured":"Wan S, Hann HW, Ye Z, Hann RS, Lai Y, Wang C, et al. Prospective and longitudinal evaluations of telomere length of circulating DNA as a risk predictor of hepatocellular carcinoma in HBV patients. Carcinogenesis. 2017;38(4):439\u201346.","journal-title":"Carcinogenesis"},{"issue":"7","key":"15339_CR44","doi-asserted-by":"publisher","first-page":"e0133174","DOI":"10.1371\/journal.pone.0133174","volume":"10","author":"C Zhang","year":"2015","unstructured":"Zhang C, Chen X, Li L, Zhou Y, Wangand C, Hou S. The association between telomere length and cancer prognosis: evidence from a meta-analysis. PLoS One. 2015;10(7):e0133174.","journal-title":"PLoS One"},{"key":"15339_CR45","doi-asserted-by":"crossref","unstructured":"Vertecchi E, Rizzoand A, Salvati E. Telomere targeting approaches in cancer: beyond length maintenance. Int J Mol Sci. 2022;23(7):3784.","DOI":"10.3390\/ijms23073784"},{"key":"15339_CR46","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2023.5526","author":"A Tsatsakis","year":"2023","unstructured":"Tsatsakis A, Oikonomopoulou T, Nikolouzakis TK, Vakonaki E, Tzatzarakis M, Flamourakis M, et al. Role of telomere length in human carcinogenesis (Review). Int J Oncol. 2023;63(1):78. https:\/\/doi.org\/10.3892\/ijo.2023.5526.","journal-title":"Int J Oncol"},{"issue":"3","key":"15339_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15339-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15339-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:42:10Z","timestamp":1781635330000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15339-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15339"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15339-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied the ethical standards for human experimentation (Helsinki Declaration). The ethics committee of the National Liver Institute approved the protocol (IRB 00135\/2019 INTM), and oral or written informed consents filled and signed by all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available due institutional policies but are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}